Navigation Links
STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
Date:4/28/2009

STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

Vancouver, B.C. (PRWEB) April 28, 2009 -- STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

MesenCult®-ACF Medium supports long-term growth of MSCs with retention of multi-lineage differentiation potential. In addition, MSCs cultured in MesenCult®-ACF Medium expand faster and show a significant reduction in hematopoietic cell contamination at early passages compared to serum-containing media.

"MesenCult®-ACF Medium is a very important addition to our product portfolio and indicates our strong interest in remaining at the cutting edge of scientific and preclinical work in the stem cell arena," says Dr. Allen Eaves, President and CEO of STEMCELL Technologies.

There is considerable interest in using mesenchymal stem cells as therapeutic agents for the treatment of a wide variety of diseases. Because of this clinical interest, there is a need to culture the cells in animal component-free culture systems, in order to minimize the risk associated with disease transmission and immune rejection of transplanted cells. The availability of MesenCult®-ACF Medium will greatly facilitate advances in efforts to assess the therapeutic relevance of mesenchymal stem cells.

Furthermore, the removal of undefined components within the medium reduces the variability traditionally associated with culture of these cells and allows for more consistent research and development work on this very important cell type.

For more information about MesenCult®-ACF Medium, please visit http://www.stemcell.com/product_catalog/hu_mesencult-acf.aspx.

Contact
Kristy Favell, MSc, Assistant Product Manager - Neural and Mesenchymal Cell Biology
STEMCELL Technologies Inc
604.668.0875

About STEMCELL Technologies
STEMCELL Technologies, a privately-owned biotechnology company, is a leader in specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science, STEMCELL delivers over 900 products to more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit www.stemcell.com

###

Read the full story at http://www.prweb.com/releases/stemcelltechnologies/mesencultacf/prweb2365414.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Dr. Susan Weinschenk, Chief of Technical Staff and Services, Speaks on Neuro Web Design at Persuasive Technologies 2009 Conference and Voices That Matter Web Design Conference
6. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
7. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
10. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
11. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):